Modalis Therapeutics Corp
TSE:4883
Relative Value
There is not enough data to reliably calculate the relative value of Modalis Therapeutics Corp.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Modalis Therapeutics Corp Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
JP |
Modalis Therapeutics Corp
TSE:4883
|
2.6B JPY | 0 | -1.1 | -0.5 | -0.5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
280.4B USD | 5.2 | 58.2 | 12.7 | 19.3 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
146.3B USD | 5.2 | 21.7 | 16.2 | 24.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 10.3 | 28.2 | 22.6 | 23.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.9B USD | 7.5 | 24.8 | 16.4 | 18 | ||
AU |
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.1 | 35.1 | 21.3 | 26.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
82.8B USD | 3.1 | 14.6 | 8 | 10.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.6 | -8.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 7.3 | 60.8 | 27.9 | 47 |